drugset / Trial / NCT01369615

Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001

NCT01369615

Phase 3 Completed 23 enrolled Purdue Pharma LP
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to characterize the long-term safety of oxycodone hydrochloride (HCl) controlled-release (CR) tablets in opioid experienced pediatric patients aged 6 to 17 years, inclusive, with moderate to severe malignant and/or nonmalignant pain requiring opioid therapy who completed the 4 -week treatment period in OTR3001.

Timeline

Start
2011-10
Primary completion
2013-12
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxycodone Other / unclassified 10 mg
Subject Oxycodone Other / unclassified 15 mg
Subject Oxycodone Other / unclassified 20 mg
Subject Oxycodone Other / unclassified 30 mg
Subject Oxycodone Other / unclassified 40 mg

Indications

No indication recorded.